ADMA (ADMA Biologics) Gross Margin % : 49.78% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. ADMA Biologics's Gross Profit for the three months ended in Sep. 2024 was $59.7 Mil. ADMA Biologics's Revenue for the three months ended in Sep. 2024 was $119.8 Mil. Therefore, ADMA Biologics's Gross Margin % for the quarter that ended in Sep. 2024 was 49.78%.

The historical rank and industry rank for ADMA Biologics's Gross Margin % or its related term are showing as below:

ADMA' s Gross Margin % Range Over the Past 10 Years
Min: -148.42 Med: 12.17 Max: 48.93
Current: 48.93

During the past 13 years, the highest Gross Margin % of ADMA Biologics was 48.93%. The lowest was -148.42%. And the median was 12.17%.

ADMA's Gross Margin % is ranked worse than
60.86% of 746 companies
in the Biotechnology industry
Industry Median: 60.565 vs ADMA: 48.93

ADMA Biologics had a gross margin of 49.78% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for ADMA Biologics was 0.00% per year.

ADMA Biologics Gross Margin % Historical Data

The historical data trend for ADMA Biologics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Gross Margin % Chart

ADMA Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

-34.60

-45.17

1.45

22.89

34.44

ADMA Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross Margin %	Get a 7-Day Free Trial															36.65	42.06	47.77	53.60	49.78

Competitive Comparison of ADMA Biologics's Gross Margin %

For the Biotechnology subindustry, ADMA Biologics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADMA Biologics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Gross Margin % falls into.

ADMA Biologics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

ADMA Biologics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	88.9	/	258.215
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(258.215 - 169.273)	/	258.215
	=	34.44 %

ADMA Biologics's Gross Margin for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )	=	Gross Profit (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	59.7	/	119.839
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(119.839 - 60.18)	/	119.839
	=	49.78 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

ADMA Biologics (NAS:ADMA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ADMA Biologics had a gross margin of 49.78% for the quarter that ended in Sep. 2024 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

ADMA Biologics Gross Margin % Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ADMA Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

465 State Route 17, Ramsey, NJ, USA, 07446

Website

https://www.admabiologics.com

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Executives

Adam S Grossman	director, officer: President and CEO	65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Jerrold B Grossman	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon	director	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Steve Elms	director	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alison Cecily Finger	director	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Brian Lenz	officer: EVP, CFO	65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond	officer: CSO/CMO	65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust	10 percent owner	C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854